This site is intended for U.S. healthcare professionals.
About
About ATTR-CM
MOD/MOA
Study Design
Menu
Close
Access & Support
Access & Patient Support
Events
Materials
Videos
Access & Patient Support
Patient access and reimbursement
Financial assistance options
Additional support during treatment
When you've decided VYNDAMAX® (tafamidis) is appropriate for your patient, VyndaLink can help*
Enroll your patients in VyndaLink for support
The VyndaLink team can:
Conduct a benefits verification to determine your patient's coverage for VYNDAMAX, including out-of-pocket costs
Determine payer requirements and provide information about the prior authorization process and appeals process as needed†
Identify Specialty Pharmacy options based on your patient’s insurance coverage. VYNDAMAX is available through multiple Specialty Pharmacies in our defined distribution network
*The same VyndaLink support offerings available to patients prescribed VYNDAMAX are also available to patients prescribed VYNDAQEL (tafamidis meglumine).
†Please note where a PA is required, the physician must submit required information directly to the patient's insurer.
Get started at www.VyndaLink.com
Download the enrollment form and fax completed forms to 1-888-878-8474. You can also complete the enrollment form online at www.VyndaLinkPortal.com. Call VyndaLink at 1-888-222-8475 (Monday-Friday, 8 AM-8 PM ET) with any questions.
Next: Financial assistance options
The card body Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam.
** This is an optional area where footnotes can live.
Access & Support
Events Materials Videos
VyndaLink.com has more information about support services for you and your patients
View VyndaLink
Access resources for you and your patient
Explore resources
Adverse Reactions
In studies in patients with ATTR-CM, the frequency of adverse events in patients treated with VYNDAQEL® (tafamidis meglumine) was similar to placebo.
Specific Populations
Pregnancy: Based on findings from animal studies, VYNDAQEL and VYNDAMAX may cause fetal harm when administered to a pregnant woman.
Lactation: There are no available data on the presence of tafamidis in human milk, the effect on the breastfed infant, or the effect on milk production. Tafamidis is present in rat milk. When a drug is present in animal milk, it is likely the drug will be present in human milk. Breastfeeding is not recommended during treatment with VYNDAQEL and VYNDAMAX.
VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
Please see Full Prescribing Information including Patient Information.
INDICATION AND LIMITATIONS OF USE
VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
Please see Full Prescribing Information including Patient Information.
Please see full Prescribing Information.
OK. We'll need you to sign in before we can determine if you are aligned with a sales representative.
If you select 'Yes', you will be required to enter your username and password in the sign-in form that will appear over this window.
Would you like to sign in now?